Navigation Links
Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
Date:12/21/2007

Researchers from the Universities of Warwick, Edinburgh, Dundee and the Czech Republics Institute of Biophysics have discovered a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use light activation to kill cancer cells in much more targeted way than similar treatments.

The platinum-based compound known as trans, trans, trans- [Pt(N3)2(OH)2(NH3)(py)], or a light activated PtIV complex, is highly stable and non-toxic if left in the dark but if light falls upon it becomes much less stable and highly toxic to cancer cells. In fact it is between 13 and 80 times more toxic (depending on how and on which cells it is used) to cancer cells than the current platinum based anti-cancer drug Cisplatin. Moreover it kills the cells by a different mechanism of action, so it can also kill cisplatin-resistant cells.

Professor Peter Sadler, Chairman of the Chemistry Department of the University of Warwick, who led the research project said:

Light activation provides its massive toxic power and also allows treatment to be targeted much more accurately against cancer cells.

The compound could be used in particular to treat surface cancers. Patients could be treated in a darkened environment with light directed specifically at cancer cells containing the compound activating the compounds toxicity and killing those cells. Normal cells exposed to the compound would be protected by keeping the patient in darkness until the compound has passed through and out of the patient.

The new light activated PtIV complex is also more efficient in its toxic action on cancer cells in that, unlike other compounds currently used in photodynamic therapy, it does not require the presence of significant amounts of oxygen within a cancer cell to become toxic. Cancer cells tend to have less oxygen present than normal cells.

Although this work is in i
'/>"/>

Contact: Peter Dunn
p.j.dunn@warwick.ac.uk
44-077-676-55860
University of Warwick
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. Study shines more light on benefit of vitamin D in fighting cancer
3. Bacteria See the Light
4. Quantum light beams good for fast technology
5. Free will takes flight: how our brains respond to an approaching menace
6. New MRI finding sheds light on multiple sclerosis disease progressio
7. RA Drugs Linked to Slight Skin Cancer Risk
8. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
9. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
10. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
11. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...g the reaction of blood vessels in the eyes may of...w blood vessels in // the brain react to high blo...w study finds the drug candesartan cilexetil, also...in the eye, which can be slowed from the result of...
...estrogen alone will not prevent chronic diseases i.... However it is found to increase // the risk of s...ding to the latest research. For the study investi...ne estrogen alone or in combination with progestin...
... have a brother with prostate cancer are twice as ...udy shows// more men realize this fact and are tak...ompared data from two studies, researchers asked m...are currently taking vitamins or supplements to pr...
...ng waistline is bad for your health, but now a new...or your health.// When a company downsizes, it of...ly, the workers are concerned about their job and ...ngly shows when a company expands quickly, workers...
Other Medicine News:
(Date:8/21/2008)....J. and EMERYVILLE, Calif., Aug. 21 /PRNewswire-Fi... and Onyx Pharmaceuticals, Inc.,(Nasdaq: ONXX ) t...patients,in the STORM Sorafenib as Adjuvant Treatm...lar Carcinoma trial. The randomized, double-blind,...xavar(R) (sorafenib),tablets as adjuvant treatment...
(Date:8/20/2008)...Aug. 20 /PRNewswire-USNewswire/ -- Graduated compr... deep vein thrombosis (DVT) in,hospitalized patien... at,risk for potentially-deadly blood clots, accor...llas., Their findings appear in the September iss...patients are at increased risk for blood clots aft...
(Date:8/19/2008)...M, Pa., Aug. 19 /- Particle Sciences ...uting polymers) development and,pilot production c...,extrusion and injection molding line. The core o...mpounding extruder and Nissei 20T injection,molder...ed polymeric,devices. This addition gives Particle...
(Date:8/18/2008)...WN, Pa., Aug. 18 /PRNewswire-USNewswire/ -- Due to...nfected mosquitoes in,southeastern Pennsylvania, t...county partners will be stepping up efforts this w...- or are most likely to carry -- the virus., Whil...een confirmed,this year (a 27-year-old Montgomery ...
Breaking Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5Dallas Researchers Find Compression Stockings Improperly Used 2Particle Sciences Expands Its Combination Product Capabilities 2Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities 2Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities 3ReBuilder Medical Technologies Inc Increases Manufacturing Space to Meet Demand 3954 1ReBuilder Medical Technologies Inc Increases Manufacturing Space to Meet Demand 3954 2ReBuilder Medical Technologies Inc Increases Manufacturing Space to Meet Demand 3954 3TopSpin Medical Appoints Cindy Setum Ph D Vice President Clinical Affairs 1321 1TopSpin Medical Appoints Cindy Setum Ph D Vice President Clinical Affairs 1321 2MultiVu Video Feed 3A Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With 22Silence the Sounds of Pertussis 22 3946 1MultiVu Video Feed 3A Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With 22Silence the Sounds of Pertussis 22 3946 2Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast Ovar 3941 1Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast Ovar 3941 2Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast Ovar 3941 3
...esults show risk of heart attack,comparable to two... , June 6, 2007 - A study,of more than 33,000 ty... published today. This study shows that the incide...r a surgery known as,coronary revascularization fo...iabetes treatments. The study results were,release...
...s lead molecule, FP0011, exhibited a differentiate...rance in mid- to,late-stage patients, STRASBOURG, ... a,clinical stage product company specializing in ...s of the nervous system, today,announced that the ...cule glutamate release inhibitor, FP0011, are bein...
Other Medicine Technology:Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders 2Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders 3Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders 4
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility
ManuTrain is an active wrist support that has optional features for increased stabilization.
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
3-Point® Polycentric Hinged Ulnar Deviation Splint uses safe, mild to moderate force to align the hand with ulnar deviation at the MP joints. Dorsal-based splint does not impede grasp or pinch. R
Medicine Products: